Rare TMA, esp. with mitomycin; mostly renally safe.

Tumor lysis-mediated AKI is the principal risk; TMA is rare.

Proteinuria, hypertension, glomerular TMA.

Rare TMA; reverses myeloma cast nephropathy.

Conditioning-regimen TMA risk.

Diarrhea-driven prerenal AKI; dose-adjust for CrCl.

AKI, TMA and hypertension — a hot myeloma signal.

Lipophilic oral 5-FU prodrug (Japan); class-level renal risk; hallmark toxicity is leukoencephalopathy not nephropathy.

Delayed interstitial fibrosis with high cumulative dose.

Tumor lysis in MDS/AML.

5'-DFUR prodrug; class-level TMA risk plus a real renal-clearance component warranting caution in renal impairment.

Dose-cumulative thrombotic microangiopathy.

Rare TMA reports.

Renally cleared; AKI and rare Fanconi/TMA.

Peptide receptor radionuclide therapy; proximal tubular radiation nephropathy is dose-limiting — amino-acid co-infusion is renoprotective.

Prototype dose-dependent TMA.

Boxed warning for capillary-leak syndrome and hemolytic-uremic syndrome / TMA.

Proteinuria and rare TMA.

Benign creatinine rise via OCT2/MATE inhibition.

Least nephrotoxic platinum; rare immune hemolysis.

Hypertension and proteinuria, class effect.

Oral tegafur+uracil; rare fluoropyrimidine-class TMA/HUS (often with mitomycin C), otherwise kidney-sparing.

Rare nodular regenerative TMA-like signals.

Hypertension as an on-target marker; proteinuria.

Hypertension and proteinuria like bevacizumab.